Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors

Bone Marrow Transplantation

Volumn 39, Issue 7, 2007, Pages 417-424

  Sobecks, R M ^a   Ball, E J ^b   Maciejewski, J P ^a   Rybicki, L A ^c   Brown, S ^a   Kalaycio, M ^a   Pohlman, B ^a   Andresen, S ^a   Theil, K S ^c   Dean, R ^a   Bolwell, B J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b WESTERN UNIVERSITY   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN; HLA BW4 ANTIGEN; HLA C ANTIGEN; HLA CW LIGAND; IMMUNOGLOBULIN RECEPTOR; KILLER IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; ENGRAFTMENT; FEMALE; GENETIC ANALYSIS; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HETEROZYGOSITY; HLA MATCHING; HOMOZYGOSITY; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; SCHOOL CHILD; SIBLING; T LYMPHOCYTE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; GRAFT VS LEUKEMIA EFFECT; HISTOCOMPATIBILITY TESTING; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33947707943     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705609     Document Type: Article

References (34)

1. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-223.
2. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
3. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
4. Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson KC et al. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722-728.
5. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
6. Farag S, Fehniger T, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
7. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998; 391: 703-707.
8. Unkeless JC, Jin J. Inhibitory receptors, ITIM sequences and phosphatases. Curr Opin Immunol 1997; 9: 338-343.
9. Vales-Gomez M, Reyburn HT, Mandelboim M, Strominger JL. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity 1998; 9: 337-344.
10. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer immunoglobulin-like receptors. Mol Immunol 2002; 38: 1007-1021.
11. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995; 181: 1133-1144.
12. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
13. Giebel S, Locatelli FW, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
14. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CIF et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521-1526.
15. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.
16. Paul P, Apgar J, Ball EJ. HLA-DRB1* intron-primed sequencing for haploid genotyping. Clin Chem 2003; 49: 692-694.
17. Paul P, Thomas D, Kawczak P, Good D, Cook DJ, Ball EJ. Resolution of cis-trans ambiguities between HLA-DRB1 alleles using single-strand conformation polymorphisms and sequencing. Tissue Antigens 2001; 57: 300-307.
18. Przepiorka D, Weisdorf D, Martin P, Klingemarm HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
19. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196-1201.
20. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650.
21. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
22. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
23. Porter DL, Collins Jr RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
24. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412.
25. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-1451.
26. + cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow. J Immunol 2002; 168: 1636-1643.
27. Tiberghien P, Longo D, Wine J, Alvord WG, Reynolds CW. Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: Evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery. Blood 1990; 76: 1419-1430.
28. Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: Witness of the past, actors of the future. Nat Rev Immunol 2004; 4: 190-198.
29. Ferrini S, Cambiaggi A, Meazza R, Sforzini S, Marciano S, Mingari MC et al. T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 functions. Eur J Immunol 1994; 24: 2294-2298.
30. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-6545.
31. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001; 166: 2992-3001.
32. Santourlidis S, Trompeter HI, Weinhold S, Eisermarm B, Meyer KL, Wernet P et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002; 169: 4253-4261.
33. Shilling HG, Guethlein LA, Cheng CM, Gardiner CM, Rodriguez R, Tyan D et al. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol 2002; 168: 2307-2315.
34. Goodridge JP, Witt CS, Christiansen FT, Warren HS. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J Immunol 2003; 171: 1768-1774.